Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

Reduced NF-κB expression linκed to postradiation oral mucosa vulnerability

The fragility of oral mucosa after radiotherapy for oral squamous cell carcinoma may be due to the inhibition of the DNA transcriptor protein nuclear factor κappa-light-chain-enhancer of activated B cells, show study findings.

6 Sep 2012

Better recognition of rising burden of cancer in Africa needed

Cancer kills more than seven million people a year throughout the world. This is more than HIV/AIDS, tuberculosis and malaria combined, and African countries, which carry a large part of the burden, are the least able of all developing countries to cope with the challenges it presents, says a consortium of international cancer organizations.

6 Sep 2012

CAD risk no higher in head and neck cancer

Researchers have shown that people with head or neck cancer are not necessarily at any greater risk for developing coronary artery disease than the general population.

4 Sep 2012

Sterotactic radiotherapy offers good results in recurrent head and neck cancer

For patients with recurring head and neck cancer, stereotactic body radiotherapy offers a feasible and tolerable salvage treatment, with median overall survival rates of more than 1 year, report researchers.

30 Aug 2012

Taking aspirin associated with reduced risk of death from prostate cancer

Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, says a new study that includes a researcher at UT Southwestern Medical Center.

29 Aug 2012

Radiating fears over diabetes in childhood cancer survivors

People who undergo pancreatic irradiation during childhood cancer therapy are at an increased risk for developing diabetes later in life, report researchers.

24 Aug 2012

Diabetes risk may be higher in childhood cancer survivors who received radiotherapy

Childhood cancer survivors who underwent radiotherapy treatment that exposed their pancreas to radiation may be at higher risk of developing diabetes in later life, according to an Article published Online First in The Lancet Oncology.

23 Aug 2012

Chemotherapy during pregnancy: an interview with Professor Sibylle Loibl

The incidence is about 1-3% of all breast cancers. The incidence seems to be increasing due to women delaying their childbearing to when they are in their thirties.

22 Aug 2012

Research explores impact of radiotherapy in older women with low risk of breast cancer recurrence

A Rhode Island Hospital radiation oncologist says in a new editorial that research exploring the impact of radiotherapy in older women with low risk of breast cancer recurrence has little effect on actual clinical decisions.

22 Aug 2012

Mayo Clinic receives approval for construction of new building on Phoenix campus

Mayo Clinic has been granted approval for construction of a 217,200 square-foot building on its Phoenix campus, a major expansion that will create a single-site, integrated Cancer Center. Mayo Clinic Cancer Center is the only National Cancer Institute-designated comprehensive cancer center with a multi-site, national presence, which allows us to serve a broad and diverse group of patients.

21 Aug 2012

HPV genotype may alter chemoradiotherapy outcome

Human papillomavirus genotype predicts whether patients with cervical cancer will benefit from concurrent chemoradiation therapy, study findings suggest.

20 Aug 2012

Targets to improve palliative patients’ wellbeing identified

Pain, depression, drowsiness, fatigue, and appetite loss are the symptoms that most affect the wellbeing of cancer patients being treated palliatively, report Canadian researchers.

16 Aug 2012

Malignant mesothelioma diagnosis with an E-nose: an interview with Associate Professor Deborah Yates, UNSW

Malignant mesothelioma is a rare tumor of the pleura which is the lining of the inside of the chest wall. It is highly linked with asbestos exposure.

16 Aug 2012

Salvage surgery for oropharyngeal cancer needs due consideration

Japanese study results indicate a 5-year overall survival rate of 49% for oropharyngeal cancer patients treated with salvage surgery after initial treatment with chemoradiotherapy has failed.

9 Aug 2012

Loyola to offer new radiotherapy system for cancer patients

A new radiotherapy system at Loyola University Medical Center will offer cancer patients shorter radiation treatments, with pinpoint accuracy and precision.

9 Aug 2012

Chemotherapy is appropriate adjunct to surgery for oral melanoma in dogs

The addition of chemotherapeutic treatment with carboplatin for dogs with oral malignant melanomas that have undergone surgical excision may be a reasonable alternative to adjunctive radiotherapy, report researchers.

8 Aug 2012

Wellcome Trust grants £1.6 million Translation Award for development of more effective radiotherapy

The Wellcome Trust has awarded a £1.6 million Translation Award to a research team led by the University of Lincoln to develop more effective radiotherapy treatment for thousands of cancer sufferers by providing unique monitoring and imaging for patients receiving proton therapy.

6 Aug 2012

CPRIT awards $48.2 million in new grants to investigators at UT Southwestern Medical Center

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded $48.2 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer researchers.

6 Aug 2012

Nanobiotix, PharmaEngine partner to develop NBTXR3 for cancer

French Nanobiotix S.A. announced today that it entered into a strategic partnership with PharmaEngine, Inc. for the rapid development of NBTXR3, the lead product from the NanoXray pipeline of Nanobiotix.

6 Aug 2012

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

PharmaEngine, Inc. announced today the execution of an exclusive license and collaboration agreement with France-based Nanobiotix S.A. for the development and commercialization of NBTXR3, currently being investigated in a phase I study with soft tissue sarcoma patients.

6 Aug 2012